

**Briefing on FY2015/3 2<sup>nd</sup> Quarter Results**  
**Main Questions and Answers**

Q1: When does the Company can start to provide Avigan fully for the treatment of Ebola Virus Disease?

A1: Currently the extralegal measures are taken between foreign governments and the Japanese government in consultation with WHO and we are responding to the requests from our government. We have stock of Avigan Tablets for 20,000 courses, which are ready to be provided if requested, as well as an additional inventory of active pharmaceutical ingredient roughly for 300,000 courses.

Q2: How does the Company forecast the performance of Healthcare business in the 2<sup>nd</sup> half of this FY?

A2: Medical Systems business has been proceeding well in line with the budget and this trend is expected to last in the 2<sup>nd</sup> half as well. Regarding Pharmaceutical business, although we are still in the stage of prior investment for R&D, we aim to realize contribution to profit as soon as possible, making clinical trials of new drugs more efficient. We expect Healthcare business to make more contribution in the 2<sup>nd</sup> half than in the 1<sup>st</sup> half.

Q3: How come the magnetic tapes for computer use from Recording Media business sell good lately?

A3: While the demand for data archiving is getting higher with growing data volume due to the spread of cloud service and such, magnetic tapes for data backup is re-evaluated with advantages in terms of cost and security over HD. In this circumstance, the sales of our products are growing, including higher-capacity tapes with our unique technology of barium ferrite (BaFe) particles.

Q4: What are the sales targets in volume of digital camera and instant camera for this fiscal year?

A4: Though we no longer pursue higher sales volume regarding digital camera, the forecasted sales volume would be about 2 million. Regarding instant camera, while we have raised the targeted volume from 3 million to 3.5 million, we aim for further sales expand.

(End)